MX357291B - Composicion derivada de osteoprotegerina y su uso. - Google Patents

Composicion derivada de osteoprotegerina y su uso.

Info

Publication number
MX357291B
MX357291B MX2014011740A MX2014011740A MX357291B MX 357291 B MX357291 B MX 357291B MX 2014011740 A MX2014011740 A MX 2014011740A MX 2014011740 A MX2014011740 A MX 2014011740A MX 357291 B MX357291 B MX 357291B
Authority
MX
Mexico
Prior art keywords
osteoprotegerin
polypeptide
derived composition
composition
human
Prior art date
Application number
MX2014011740A
Other languages
English (en)
Other versions
MX2014011740A (es
Inventor
Lavrovsky Yan
Xu Ting
Repik Alexey
Guo Kangping
Samsonov Mikhail
Ignatiev Vasily
Original Assignee
R Pharm Cjsc Closed Joint Stock Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Cjsc Closed Joint Stock Company filed Critical R Pharm Cjsc Closed Joint Stock Company
Publication of MX2014011740A publication Critical patent/MX2014011740A/es
Publication of MX357291B publication Critical patent/MX357291B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición terapéutica que puede utilizarse para tratar o prevenir enfermedades asociadas con la resorción, particularmente de un carcinoma metastático. En ciertos aspectos, la composición se base en un polipéptido que incluye 215 aminoácidos principales de osteoprotegerina humana seguido por la porción Fc de la proteína IgG1 humana. Los vectores de expresión de ADN y los sistemas de expresión para la sobre-producción del polipéptido en células de mamífero también son provistos.
MX2014011740A 2012-03-31 2012-03-31 Composicion derivada de osteoprotegerina y su uso. MX357291B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/031737 WO2013147899A1 (en) 2012-03-31 2012-03-31 Osteoprotegerin derived composition and use thereof

Publications (2)

Publication Number Publication Date
MX2014011740A MX2014011740A (es) 2015-11-13
MX357291B true MX357291B (es) 2018-07-04

Family

ID=49260952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011740A MX357291B (es) 2012-03-31 2012-03-31 Composicion derivada de osteoprotegerina y su uso.

Country Status (15)

Country Link
EP (1) EP2874643B1 (es)
JP (1) JP6431476B2 (es)
CN (1) CN104640557A (es)
AU (1) AU2012375257B2 (es)
BR (1) BR112014024398B1 (es)
CA (1) CA2868759A1 (es)
EA (1) EA034861B1 (es)
HK (1) HK1210725A1 (es)
HR (1) HRP20191494T1 (es)
IL (1) IL234915B (es)
MX (1) MX357291B (es)
PH (1) PH12014502198A1 (es)
PL (1) PL2874643T3 (es)
SG (1) SG11201406216XA (es)
WO (1) WO2013147899A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134032A1 (en) * 2014-03-06 2015-09-11 R-Pharm Overseas, Inc. Osteoprotegerin derived rankl inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604624A4 (en) * 1992-06-22 1997-03-12 Miles Inc MULTIMER FORMS OF HUMAN RHINOVIRUS RECEPTOR PROTEIN.
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US20030144187A1 (en) * 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
CA2349406C (en) * 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
US7459426B2 (en) * 2004-06-04 2008-12-02 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
CN102276727B (zh) * 2011-08-01 2013-10-16 首都医科大学 IL-17RC-hFc融合蛋白及其应用

Also Published As

Publication number Publication date
EA201400959A1 (ru) 2015-03-31
SG11201406216XA (en) 2015-03-30
JP6431476B2 (ja) 2018-11-28
EA034861B1 (ru) 2020-03-30
AU2012375257A1 (en) 2014-10-23
MX2014011740A (es) 2015-11-13
PH12014502198B1 (en) 2014-12-10
EP2874643A1 (en) 2015-05-27
JP2015514082A (ja) 2015-05-18
PH12014502198A1 (en) 2014-12-10
BR112014024398B1 (pt) 2022-03-08
EP2874643A4 (en) 2016-03-30
HK1210725A1 (en) 2016-05-06
BR112014024398A2 (pt) 2017-08-08
AU2012375257B2 (en) 2019-09-12
IL234915A0 (en) 2014-12-31
EP2874643B1 (en) 2019-06-26
IL234915B (en) 2019-05-30
WO2013147899A1 (en) 2013-10-03
CN104640557A (zh) 2015-05-20
HRP20191494T1 (hr) 2019-11-29
PL2874643T3 (pl) 2019-12-31
CA2868759A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IN2014CN04498A (es)
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
MX2017014716A (es) Polipeptido de fusion anti-cancer.
TN2014000109A1 (en) Fusion proteins for treating metabolic disorders
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
PH12014501363A1 (en) Anticancer fusion protein
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ603200A (en) Peptides and their use
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
MX337436B (es) Proteina de funsion anticancer.
IN2012DN02981A (es)
MX2013007872A (es) Proteina de fusion anticancer.
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX350445B (es) Analogos del factor b del complemento y sus usos.
NZ592911A (en) Leukolectins and uses thereof
PH12015501796A1 (en) Il-1b inhibitor composition and use thereof
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
NZ610620A (en) Inhibitors of apoptosis and uses thereof
PL394618A1 (pl) Przeciwnowotworowe bialko fuzyjne

Legal Events

Date Code Title Description
FG Grant or registration